Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P. Coppieters K, et al. Among authors: silence k. Arthritis Rheum. 2006 Jun;54(6):1856-66. doi: 10.1002/art.21827. Arthritis Rheum. 2006. PMID: 16736523 Free article.
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.
Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB. Ulrichts H, et al. Among authors: silence k. Blood. 2011 Jul 21;118(3):757-65. doi: 10.1182/blood-2010-11-317859. Epub 2011 May 16. Blood. 2011. PMID: 21576702 Free article.
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P. Hultberg A, et al. Among authors: silence k. Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3. Cancer Res. 2015. PMID: 26141862 Free article.
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Aftimos P, et al. Among authors: silence k. Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765328 Clinical Trial.
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.
Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P. Jacobs J, et al. Among authors: silence k. Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088768 Free PMC article.
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.
Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, Bos JW, Jansen MD, Curial CAD, Silence K, de Haard H, Blanchetot C, Van de Ven L, Leusen JHW, Pasterkamp RJ, van den Berg LH, Hack CE, Boross P, van der Pol WL. Budding K, et al. Among authors: silence k. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1107. doi: 10.1212/NXI.0000000000001107. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34759020 Free PMC article.
ARGX-117, a therapeutic complement inhibiting antibody targeting C2.
Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. Van de Walle I, et al. Among authors: silence k. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. doi: 10.1016/j.jaci.2020.08.028. Epub 2020 Sep 11. J Allergy Clin Immunol. 2021. PMID: 32926878 Free PMC article.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M. Leupin N, et al. Among authors: silence k. Cancer. 2022 Mar 1;128(5):1004-1014. doi: 10.1002/cncr.34005. Epub 2021 Nov 2. Cancer. 2022. PMID: 34726773 Free article. Clinical Trial.
26 results